Home > Financial Ratios > NATCO PHARMA

NATCO PHARMA
Core EBITDA Growth

    Back to All Ratios
NATCO PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results

NATCO PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Growth(%) 80.69186.95-48.932.87-25.41

What is the latest Core EBITDA Growth ratio of NATCO PHARMA ?

The latest Core EBITDA Growth ratio of NATCO PHARMA is 80.69 based on Mar2024 Consolidated results.
Year Core EBITDA Growth
Mar202480.69
Mar2023186.95
Mar2022-48.93
Mar20212.87
Mar2020-25.41

How is Core EBITDA Growth of NATCO PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2024 80.69
-56.84
Mar2023 186.95
Positive
Mar2022 -48.93
Negative
Mar2021 2.87
Positive
Mar2020 -25.41 -

Other Financial Ratios of NATCO PHARMA


Compare Core EBITDA Growth ratio of peers of NATCO PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
NATCO PHARMA ₹14,868.9 Cr -6% 3.2% -15.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹436,379.0 Cr 0.8% 7.2% 22.2% Stock Analytics
DIVIS LABORATORIES ₹163,420.0 Cr 0.7% 11% 53.3% Stock Analytics
CIPLA ₹122,010.0 Cr -2% 4.6% 10.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹110,634.0 Cr -1.6% 2.8% 24.4% Stock Analytics
DR REDDYS LABORATORIES ₹96,788.5 Cr -1.4% 0.7% -5.5% Stock Analytics


NATCO PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
NATCO PHARMA

-6%

3.2%

-15.9%

SENSEX

0.5%

4.2%

8%


You may also like the below Video Courses